Ruxolitinib compared with best available therapy for essential thrombocythaemia patients resistant or intolerant to hydroxycarbamide in majic: an investigator lead randomized trial by Harrison, C, Mead, A, Panchal, A, Fox, S, Yap, C, Houlton, A, Aliman, S, Wood, M, Chen, F, Coppell, J, Panoskaltsis, N, Scherber, R, Geyer, H, Dueck, A, Mesa, R, McMullin, M

Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial by Harrison, C, Mead, A, Panchal, A, Fox, S, Yap, C, Gbandi, E, Houlton, A, Alimam, S, Ewing, J, Wood, M, Chen, F, Coppell, J, Panoskaltsis, N, Knapper, S, Ali, S, Hamblin, A, Scherber, R, Dueck, A, Cross, N, Mesa, R, McMullin, M

Correlation between treatment outcomes, baseline characteristics and molecular responses in the Majic study which compared Ruxolitinib to best available therapy in essential thromb... by Harrison, C, Mead, A, Fox, S, Panchal, A, Yap, C, Houlton, A, Aliman, S, Ewing, J, Wood, M, Chen, F, Coppell, J, Panoskaltsis, N, Knapper, S, Ali, S, Hamblin, A, Scherber, R, Geyer, H, Scotch, A, Dueck, A, Cross, N, Mesa, R, McMullin, M